AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32819304 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control (CON)
Number of subjects: 17
Study 35737919 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab plus Olaparib (1,500 mg intravenously once every 4 weeks + 300 mg orally, twice daily)
Number of subjects: 154
Study 35737919 — intervention group
Group type: COMPARATOR
Intervention: Durvalumab plus Placebo
Number of subjects: 154
Study 35737919 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab plus Olaparib
Number of subjects: 154
Study 33881748 — intervention group
Group type: EXPERIMENTAL
Intervention: 1RM-TRAIN
Number of subjects: 151
Study 33881748 — intervention group
Group type: EXPERIMENTAL
Intervention: TRAD-TRAIN
Number of subjects: 151
Study 33881748 — intervention group
Group type: COMPARATOR
Intervention: CONTROL
Number of subjects: 151
Study 32828349 — intervention group
Group type: EXPERIMENTAL
Intervention: Training based on a Nursing Module on abuse among women with mental illness
Number of subjects: 68
Study 32828349 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 68
Study 36261594 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured Water Dance Intervention (SWAN), administered for 40 minutes once a week during a 12-week period.
Number of subjects: 34
Study 33839923 — intervention group
Group type: EXPERIMENTAL
Intervention: Anemia group (hemoglobin < 12 g/dL for women and < 13 g/dL for men)
Number of subjects: 1721
Study 33839923 — intervention group
Group type: COMPARATOR
Intervention: Non-anemia group
Number of subjects: 1721
Study 34647600 — intervention group
Group type: EXPERIMENTAL
Intervention: Males at 3 months (mean LAZ: -0.94) vs Females (mean LAZ: -0.74)
Number of subjects: 1084
Study 34647600 — intervention group
Group type: EXPERIMENTAL
Intervention: Males at 3 months (mean WAZ: -0.63) vs Females (mean WAZ: -0.48)
Number of subjects: 1084
Study 34647600 — intervention group
Group type: EXPERIMENTAL
Intervention: Males with illness at 3 months (ΔWAZ: -0.24) vs Females with illness (ΔWAZ: 0.03)
Number of subjects: 1084
Study 34454674 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus chemotherapy
Number of subjects: 749
Study 34454674 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus chemotherapy
Number of subjects: 749
Study 32618212 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Music (GM) - 30-minute musical intervention before chemotherapy
Number of subjects: 0
Study 32618212 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Music (GM)
Number of subjects: 0
Study 32618212 — intervention group
Group type: COMPARATOR
Intervention: Group Control (GC)
Number of subjects: 0
Study 35703758 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored Motivational Interviewing (TMI)
Number of subjects: 151
Study 35703758 — intervention group
Group type: COMPARATOR
Intervention: Communities of practice guidance with or without internal facilitator support
Number of subjects: 151
Study 33990120 — intervention group
Group type: EXPERIMENTAL
Intervention: CRC screening education intervention
Number of subjects: 0
Study 33183668 — intervention group
Group type: EXPERIMENTAL
Intervention: PT + BT
Number of subjects: 270
Study 33183668 — intervention group
Group type: COMPARATOR
Intervention: PT
Number of subjects: 270
Study 35548423 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive cardiac surgery-coronary artery bypass grafting (MICS-CABG)
Number of subjects: 248
Study 35548423 — intervention group
Group type: COMPARATOR
Intervention: CABG (control group)
Number of subjects: 248
Study 34560835 — intervention group
Group type: COMPARATOR
Intervention: Remifentanil plasma target concentration 0 ng/ml (Group R0)
Number of subjects: 52
Study 34560835 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil plasma target concentration 1 ng/ml (Group R1)
Number of subjects: 52
Study 34560835 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil plasma target concentration 2 ng/ml (Group R2)
Number of subjects: 52
Study 35636696 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib plus Bevacizumab (80 mg daily + 15 mg/kg every 3 weeks)
Number of subjects: 122
Study 35636696 — intervention group
Group type: COMPARATOR
Intervention: Osimertinib monotherapy
Number of subjects: 122
Study 35636696 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib plus Bevacizumab
Number of subjects: 122
Study 36156930 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram risk prediction score for severity of AHTGP (referred to as AAP)
Number of subjects: 243
Study 33079474 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led hypertension management program (20 weeks of health education and motivational meetings)
Number of subjects: 74
Study 33079474 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 74
Study 37003126 — intervention group
Group type: EXPERIMENTAL
Intervention: Handgrip strength (HGS) measured using a dynamometer
Number of subjects: 116
Study 37003126 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayley Scales of Infant Development‐III for neurodevelopment assessment
Number of subjects: 116
Study 37003126 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple regression analysis
Number of subjects: 116
Study 37003126 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal education level
Number of subjects: 116
Study 34383312 — intervention group
Group type: COMPARATOR
Intervention: Ataluren
Number of subjects: 0
Study 34383312 — intervention group
Group type: COMPARATOR
Intervention: Deflazacort
Number of subjects: 0
Study 32115998 — intervention group
Group type: EXPERIMENTAL
Intervention: Body diversity images
Number of subjects: 106
Study 32115998 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 106
Study 32115998 — intervention group
Group type: EXPERIMENTAL
Intervention: Thin-ideal images
Number of subjects: 106
Study 34995100 — intervention group
Group type: EXPERIMENTAL
Intervention: PRO-based symptom management
Number of subjects: 166
Study 34995100 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 166
Study 34682522 — intervention group
Group type: EXPERIMENTAL
Intervention: High Intensity Training (HIT)
Number of subjects: 35
Study 34682522 — intervention group
Group type: COMPARATOR
Intervention: Moderate Intensity Training (MIT)
Number of subjects: 35
Study 33125478 — intervention group
Group type: EXPERIMENTAL
Intervention: High insoluble fiber (ISF) diet
Number of subjects: 60
Study 33125478 — intervention group
Group type: EXPERIMENTAL
Intervention: High soluble fiber (SF) diet
Number of subjects: 60
Study 33125478 — intervention group
Group type: COMPARATOR
Intervention: Normal level of dietary fiber (CON)
Number of subjects: 60
Study 35020052 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) 500 mg daily for 12 months
Number of subjects: 332
Study 35020052 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 332
Study 33522997 — intervention group
Group type: EXPERIMENTAL
Intervention: T2WI-derived MDF values
Number of subjects: 85
Study 33522997 — intervention group
Group type: EXPERIMENTAL
Intervention: ADC-derived MDF values
Number of subjects: 85
Study 35416981 — intervention group
Group type: EXPERIMENTAL
Intervention: Exendin-(9-39) 0.44 mg/kg
Number of subjects: 16
Study 35416981 — intervention group
Group type: EXPERIMENTAL
Intervention: Exendin-(9-39) 0.6 mg/kg during MMTT
Number of subjects: 16
Study 35416981 — intervention group
Group type: EXPERIMENTAL
Intervention: Exendin-(9-39) 0.6 mg/kg during OPTT
Number of subjects: 16
Study 35416981 — intervention group
Group type: EXPERIMENTAL
Intervention: Exendin-(9-39) 0.6 mg/kg
Number of subjects: 16
Study 35416981 — intervention group
Group type: EXPERIMENTAL
Intervention: Exendin-(9-39) during OPTT
Number of subjects: 16
Study 32847444 — intervention group
Group type: EXPERIMENTAL
Intervention: Changweishu combined with routine Western medicine treatment
Number of subjects: 50
Study 32847444 — intervention group
Group type: COMPARATOR
Intervention: Routine Western medicine treatments (meropenem, noradrenaline, glutamine glue, Bifidobacterium lactis triple‐strain tablet)
Number of subjects: 50
Study 35760724 — intervention group
Group type: EXPERIMENTAL
Intervention: Stratified exercise therapy (including dietary intervention for obesity subgroup)
Number of subjects: 335
Study 35760724 — intervention group
Group type: COMPARATOR
Intervention: Usual exercise therapy (control)
Number of subjects: 335
Study 33910091 — intervention group
Group type: EXPERIMENTAL
Intervention: Technology Supported Mindfulness training (TSM) using the 'Muse' device for 8 weeks
Number of subjects: 71
Study 33910091 — intervention group
Group type: COMPARATOR
Intervention: Wait list control for 8 weeks
Number of subjects: 71
Study 35466705 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Orientation to Occupational Performance intervention (one hour weekly for 10 weeks)
Number of subjects: 78
Study 34525990 — intervention group
Group type: EXPERIMENTAL
Intervention: H2GO! intervention
Number of subjects: 450
Study 34525990 — intervention group
Group type: COMPARATOR
Intervention: Usual care control (wait-list)
Number of subjects: 450
Study 36203988 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Mediterranean Diet A (MMD A)
Number of subjects: 95
Study 36203988 — intervention group
Group type: COMPARATOR
Intervention: Modified Mediterranean Diet B (MMD B)
Number of subjects: 95
Study 33471146 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg ketamine infusion
Number of subjects: 71
Study 33471146 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg ketamine infusion
Number of subjects: 71
Study 33471146 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 71
Study 32091429 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction-based decision rule
Number of subjects: 0
Study 32091429 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 0
Study 35148626 — intervention group
Group type: EXPERIMENTAL
Intervention: Sterile polyacrylate wound pad with activated carbon cloth treatment
Number of subjects: 77
Study 35148626 — intervention group
Group type: COMPARATOR
Intervention: Standard non-adhesive hydrocellular foam dressing with silver
Number of subjects: 77
Study 35148626 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 77
Study 34587943 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg plus ezetimibe 10 mg
Number of subjects: 101
Study 34587943 — intervention group
Group type: COMPARATOR
Intervention: Rosuvastatin 20 mg
Number of subjects: 101
Study 32728546 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide nasal douching
Number of subjects: 60
Study 32728546 — intervention group
Group type: COMPARATOR
Intervention: Standard postoperative regimen (Control)
Number of subjects: 60
Study 35494521 — intervention group
Group type: EXPERIMENTAL
Intervention: Aqua astricta flushing (refrigerated normal saline)
Number of subjects: 185
Study 35494521 — intervention group
Group type: COMPARATOR
Intervention: Normal temperature saline (control)
Number of subjects: 185
Study 32664145 — intervention group
Group type: EXPERIMENTAL
Intervention: Bushen Yisui and Ziyin Jiangzhuo (BYZJ) granules administered twice daily for 4 weeks
Number of subjects: 90
Study 32664145 — intervention group
Group type: COMPARATOR
Intervention: Placebo (simulated granules) administered twice daily for 4 weeks
Number of subjects: 90
Study 32664145 — intervention group
Group type: EXPERIMENTAL
Intervention: Bushen Yisui and Ziyin Jiangzhuo (BYZJ) granules
Number of subjects: 90
Study 32664145 — intervention group
Group type: COMPARATOR
Intervention: Placebo (simulated granules)
Number of subjects: 90
Study 33555720 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure (12 sessions over 4 weeks)
Number of subjects: 0
Study 32055822 — intervention group
Group type: EXPERIMENTAL
Intervention: PF‐06412562 (3 mg twice daily)
Number of subjects: 77
Study 32055822 — intervention group
Group type: EXPERIMENTAL
Intervention: PF‐06412562 (15 mg twice daily)
Number of subjects: 77
Study 32055822 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study 32055822 — intervention group
Group type: EXPERIMENTAL
Intervention: PF‐06412562 (3 mg twice daily) and PF‐06412562 (15 mg twice daily)
Number of subjects: 77
Study 34864737 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 61
Study 34864737 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Continuous Training (MICT)
Number of subjects: 61
Study 34864737 — intervention group
Group type: COMPARATOR
Intervention: Control (CTR, without training)
Number of subjects: 61
Study 34004482 — intervention group
Group type: EXPERIMENTAL
Intervention: LDLMartin
Number of subjects: 6701
Study 34004482 — intervention group
Group type: EXPERIMENTAL
Intervention: LDLSampson
Number of subjects: 6701
Study 34004482 — intervention group
Group type: COMPARATOR
Intervention: LDLFriedewald
Number of subjects: 6701
Study 32022990 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus
Number of subjects: 100
Study 32022990 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus
Number of subjects: 100
Study 35197189 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized delirium prevention and treatment measures
Number of subjects: 772
Study 35197189 — intervention group
Group type: COMPARATOR
Intervention: No standardized delirium prevention and treatment measures (control)
Number of subjects: 772
Study 34684351 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginseng Extract 3 g
Number of subjects: 90
Study 34684351 — intervention group
Group type: COMPARATOR
Intervention: Ginseng Extract 1 g
Number of subjects: 90
Study 34684351 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 36058804 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic Diagnosis-guided Laser Photocoagulation of Bladder Tumor (PC-BT) in outpatient department using a 980 nm diode laser
Number of subjects: 206
Study 36058804 — intervention group
Group type: COMPARATOR
Intervention: Transurethral Resection of Bladder Tumor (TUR-BT) in general anesthesia
Number of subjects: 206
Study 33060549 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroboscopic vision
Number of subjects: 32
Study 33060549 — intervention group
Group type: COMPARATOR
Intervention: Normal vision (Control)
Number of subjects: 32
Study 32655129 — intervention group
Group type: EXPERIMENTAL
Intervention: HDAC3 alteration via lentivirus vectors in GC cell line BGC-823/AGS
Number of subjects: 64
Study 32655129 — intervention group
Group type: EXPERIMENTAL
Intervention: HDAC3 treatment in GC cells
Number of subjects: 64
Study 32655129 — intervention group
Group type: EXPERIMENTAL
Intervention: FOXA2 binding to FTO gene promoter
Number of subjects: 64
Study 32655129 — intervention group
Group type: EXPERIMENTAL
Intervention: FTO stabilization of MYC mRNA
Number of subjects: 64
Study 32655129 — intervention group
Group type: EXPERIMENTAL
Intervention: In vivo animal study of GC cell tumorigenesis in nude mice
Number of subjects: 64
Study 32121111 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent energy restriction
Number of subjects: 43
Study 32121111 — intervention group
Group type: COMPARATOR
Intervention: Continuous energy restriction
Number of subjects: 43
Study 32121111 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 43
Study 35673804 — intervention group
Group type: EXPERIMENTAL
Intervention: Scalp acupuncture combined with rehabilitation treatment (SR group)
Number of subjects: 108
Study 35673804 — intervention group
Group type: COMPARATOR
Intervention: Rehabilitation treatment alone (RE group)
Number of subjects: 108
Study 32322943 — intervention group
Group type: COMPARATOR
Intervention: Subchondral injection of MSCs (from iliac bone marrow concentrate), 20 cm3 volume (10 cc in tibia and 10 cc in femur), average 7800 MSCs/mL.
Number of subjects: 140
Study 32322943 — intervention group
Group type: COMPARATOR
Intervention: Total knee arthroplasty (TKA) on one side (control group).
Number of subjects: 140
Study 34231275 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethics Quarter intervention (12 sessions of 15 minutes each over 6 weeks)
Number of subjects: 341
Study 34231275 — intervention group
Group type: COMPARATOR
Intervention: Standard organisational ethics structures (control group)
Number of subjects: 341
Study 32484129 — intervention group
Group type: EXPERIMENTAL
Intervention: Improvised renal replacement therapy (ImpRRT)
Number of subjects: 12
Study 32484129 — intervention group
Group type: COMPARATOR
Intervention: Continuous renal replacement therapy (CRRT)
Number of subjects: 12
Study 32484129 — intervention group
Group type: EXPERIMENTAL
Intervention: ImpRRT
Number of subjects: 12
Study 32484129 — intervention group
Group type: COMPARATOR
Intervention: CRRT
Number of subjects: 12
Study 32957571 — intervention group
Group type: EXPERIMENTAL
Intervention: Quercetin (1000 mg/day)
Number of subjects: 16
Study 32957571 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 16
Study 35276922 — intervention group
Group type: EXPERIMENTAL
Intervention: High-quality, optimal protein diet (1.9 g·kg−1·d−1)
Number of subjects: 6
Study 35276922 — intervention group
Group type: COMPARATOR
Intervention: Adequate protein diet (1.2 g·kg−1·d−1)
Number of subjects: 6
Study 34042954 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiparametric magnetic resonance imaging-targeted biopsy
Number of subjects: 0
Study 34042954 — intervention group
Group type: COMPARATOR
Intervention: Systematic transrectal ultrasonography biopsy
Number of subjects: 0
Study 32096451 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-Coated Balloon (DCB)
Number of subjects: 88
Study 32096451 — intervention group
Group type: COMPARATOR
Intervention: Uncoated Balloon
Number of subjects: 88
Study 35435467 — intervention group
Group type: EXPERIMENTAL
Intervention: Substituting non-irritants (water or milk)
Number of subjects: 105
Study 35435467 — intervention group
Group type: COMPARATOR
Intervention: Healthy eating
Number of subjects: 105
Study 34330599 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucantime®
Number of subjects: 33
Study 34330599 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucantime® + Oral Tamoxifen
Number of subjects: 33
Study 34330599 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucantime® + Topical Tamoxifen
Number of subjects: 33
Study 34330599 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 33
Study 33156688 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast milk for oral care
Number of subjects: 50
Study 33156688 — intervention group
Group type: COMPARATOR
Intervention: Sodium bicarbonate solution for oral care
Number of subjects: 50
Study 32683550 — intervention group
Group type: EXPERIMENTAL
Intervention: AI system for segmentation and quantification of COVID-19 lung regions
Number of subjects: 204
Study 32683550 — intervention group
Group type: EXPERIMENTAL
Intervention: Computed imaging biomarkers (portion of infection and average infection HU)
Number of subjects: 204
Study 32683550 — intervention group
Group type: EXPERIMENTAL
Intervention: AI system evaluating changes in infection volumes
Number of subjects: 204
Study 33694338 — intervention group
Group type: EXPERIMENTAL
Intervention: OMT+BEMER
Number of subjects: 40
Study 33694338 — intervention group
Group type: COMPARATOR
Intervention: OMT only
Number of subjects: 40
Study 33694338 — intervention group
Group type: COMPARATOR
Intervention: BEMER only
Number of subjects: 40
Study 33694338 — intervention group
Group type: COMPARATOR
Intervention: Control (light touch and sham)
Number of subjects: 40
Study 32483675 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorzolamide
Number of subjects: 658
Study 32483675 — intervention group
Group type: EXPERIMENTAL
Intervention: Brinzolamide
Number of subjects: 658
Study 32483675 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% Betaxolol
Number of subjects: 658
Study 32483675 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% Timolol Gel
Number of subjects: 658
Study 32483675 — intervention group
Group type: COMPARATOR
Intervention: 0.5% Timolol Gel
Number of subjects: 658
Study 32483675 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost
Number of subjects: 658
Study 32483675 — intervention group
Group type: EXPERIMENTAL
Intervention: Travoprost
Number of subjects: 658
Study 32483675 — intervention group
Group type: COMPARATOR
Intervention: Beta-blockers
Number of subjects: 658
Study 32483675 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbonic Anhydrase Inhibitors (CAI)
Number of subjects: 658
Study 32483675 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandins
Number of subjects: 658
Study 36283760 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported outcome measures intervention
Number of subjects: 779
Study 36283760 — intervention group
Group type: COMPARATOR
Intervention: Control group (no patient-reported outcome measures)
Number of subjects: 779
Study 33757513 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlusal trauma plus moderate orthodontic forces group
Number of subjects: 40
Study 33757513 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate orthodontic forces group
Number of subjects: 40
Study 33757513 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlusal trauma group
Number of subjects: 40
Study 33757513 — intervention group
Group type: COMPARATOR
Intervention: Healthy pulp control group
Number of subjects: 40
Study 36273314 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 μg GCSF administered intrauterine with hCG injection
Number of subjects: 320
Study 36273314 — intervention group
Group type: COMPARATOR
Intervention: Normal saline administered intrauterine with hCG injection
Number of subjects: 320
Study 36361434 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise training (RT) for 24 weeks, 60 min per session, 2 sessions per week
Number of subjects: 30
Study 36361434 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 30
Study 32317122 — intervention group
Group type: EXPERIMENTAL
Intervention: Podcast with interpolated questions (n=68)
Number of subjects: 137
Study 32317122 — intervention group
Group type: COMPARATOR
Intervention: Podcast without interpolated questions (n=69)
Number of subjects: 137
Study 36368750 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone 1 g
Number of subjects: 0
Study 36368750 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefixime 400 mg
Number of subjects: 0
Study 36368750 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone 500 mg plus 2 g azithromycin
Number of subjects: 0
Study 32620345 — intervention group
Group type: EXPERIMENTAL
Intervention: Aurai water propelled, heating Eye Massager (AEM) used twice a day for 2 weeks
Number of subjects: 15